-+ 0.00%
-+ 0.00%
-+ 0.00%

Impilo portfolio firm Immedica wins FDA accelerated approval for Loargys in hyperargininemia

PUBT·09/04/2026 15:02:39
Listen to the news
Impilo portfolio firm Immedica wins FDA accelerated approval for Loargys in hyperargininemia
  • Impilo portfolio company Immedica secured FDA accelerated approval for Loargys (pegzilarginase-nbln) to treat hyperargininemia in ARG1-D patients.
  • Label covers adults plus children aged 2 years and older; therapy used alongside dietary protein restriction.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impilo AB published the original content used to generate this news brief on September 04, 2026, and is solely responsible for the information contained therein.